Prophylaxis News and Research

RSS

JAIDS presents important information to prevent HIV epidemic among transgender individuals

Programs to reduce the high risk of HIV infection among transgender people are urgently needed—but efforts are hindered by a lack of accurate information on HIV prevalence, HIV incidence, and specific risk factors facing this key population.

20 Jul 2016

Study confirms efficacy of PrEP in reducing risk of HIV infection in men who have sex with men

The last phase of ANRS IPERGAY has confirmed that "on-demand" pre-exposure prophylaxis (PrEP) is a highly effective method of reducing the risk of HIV infection in men who have sex with men and who report high-risk behavior.

20 Jul 2016

Maternal antiretroviral treatment eliminates HIV transmission to infants during breastfeeding

For HIV-infected mothers whose immune system is in good health, taking a three-drug antiretroviral regimen during breastfeeding essentially eliminates HIV transmission by breast milk to their infants, according to results from a large clinical trial conducted in sub-Saharan Africa and India.

19 Jul 2016

HOPE study seeks to understand safety of vaginal ring in protecting women against HIV

Women who took part in ASPIRE, a trial that found a vaginal ring containing an antiretroviral (ARV) drug called dapivirine was safe and helped protect against HIV, will soon be offered the opportunity to use the ring as part of a new study called HOPE.

19 Jul 2016

Studies shed new light on why young women in South Africa experience high rates of HIV infection

Evidence by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) consortium of South African and North American researchers will be presented on July 18 at the International AIDS 2016 Conference in Durban, shedding new light on why young women in South Africa have high rates of HIV infection.

18 Jul 2016

Researchers receive grant to test transcutaneously refillable implant that delivers HIV-prevention drugs

A Houston Methodist research team received a nearly $4 million grant to test a transcutaneously refillable implant that administers pre-exposure prophylaxis drugs to subjects at risk of HIV-exposure.

13 Jul 2016

CNIO study shows proinflammatory molecule IL-17A can be key factor in development of NASH and HCC

Non-alcoholic steatohepatitis (NASH) is a serious hepatic condition that precedes hepatocellular carcinoma (HCC) and is currently untreatable.

12 Jul 2016

Study highlights ongoing global epidemic of HIV among gay men

Gay, bisexual and other men who have sex with men continue to have disproportionately high burdens of HIV infection in countries of low, middle and high income around the world, a new study led by the Johns Hopkins Bloomberg School of Public Health suggests.

8 Jul 2016

Implementation science may help prevent mother-to-child HIV transmissions

An emerging field, known as implementation science, may help reduce the nearly 150,000 instances of mother-to-child HIV transmissions that occur annually around the world, mostly in developing countries. c

1 Jul 2016

New superbug test developed by TGen-NAU receives Australian patent

Antibiotic-resistant infections should be easier to detect, and hospitals could become safer, thanks to a technology developed by the Translational Genomics Research Institute and Northern Arizona University, and protected under a patent issued by Australia.

16 Jun 2016

Topical delivery of AVR drug combination can provide complete protection against HIV

Researchers are edging ever closer to discovering the perfect combination of drugs and drug delivery system that will stop the sexual transmission of HIV.

14 Jun 2016

Controlling corneal blindness by 2030: an interview with Dr Pravin Vaddavalli

Corneal blindness is estimated to be the second most prevalent cause of blindness in many less developed countries. Globally, bilateral corneal blindness is estimated to afflict 4.9 million persons and accounts for 12% of 39 million blind, utilizing WHO 2010 global blindness data.

13 Jun 2016

Coagadex now available for rare bleeding disorder patients in the UK

Bio Products Laboratory, Limited (BPL) today announced that Coagadex is now available for patients in the UK.

7 Jun 2016

NHS England takes too long to commission PrEP for HIV prevention

An effective treatment that can prevent HIV infection and reduce the human and financial costs of the preventable condition is taking too long to be commissioned and made available on the NHS, warns Deborah Gold, chief executive of the National Aids Trust, in an article published by The BMJ today.

7 Jun 2016

$Allogeneic HSCT offers good survival for select TKI-refractory CML patients$

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Allogeneic hematopoietic stem cell transplantation is associated with a high rate of survival for carefully chosen chronic myeloid leukaemia patients who do not respond well to tyrosine kinase inhibitor therapy, research suggests.

18 May 2016

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

AbbVie, a global biopharmaceutical company, today announced The Lancet Oncology published results from the Phase 2, single arm, open label trial studying venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) with 17p deletion.

17 May 2016

Simple, cheap chemical sensors may detect developing cancers in future

Many cancers could be successfully treated if the patient consulted the doctor sufficiently early. But how can a developing cancer be detected if it doesn't give rise to any symptoms? In the near future, suitably early diagnosis could be provided by simple and cheap chemical sensors - thanks to special recognizing polymer films developed at the Institute of Physical Chemistry of the Polish Academy of Sciences in Warsaw.

12 May 2016

New antibody-based therapy may provide better strategy for long-term control of HIV

The development of antiretroviral therapy, a combination of drugs that slows the replication of HIV in the body, has transformed the treatment of this infection. What was once a certain death sentence is now a chronic condition that people can live with for decades.

9 May 2016

Key opinions leaders to discuss role of cyclophosphamide in the field of HSCT

Key opinions leaders in the field of haematopoetic stem cell transplantation (HSCT) will address the role of Cyclophosphamide, an anti-cancer chemotherapy drug, during the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) that will welcome more than 4,500 delegates in the host city of Valencia, Spain from the 3rd to the 6th of April 2016.

31 Mar 2016

European Medicines Agency approves first-ever treatment for hereditary factor X deficiency

Bio Products Laboratory, Limited (BPL) today announced that the European Medicines Agency has granted marketing authorisation for Coagadex.